Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease

Prostate specific membrane antigen (PSMA) is a 750 amino acid, type II transmembrane glycoprotein that has been shown to be over-expressed in both prostate cancer cells and the vasculature of solid tumours.1 Also known as folate dehydrolase, glutamate carboxypeptidase II or N-acetyl-L-aspartyl-L-glutamate peptidase I,2 PSMA has numerous metabolic roles and high levels of expression have been associated with tumour aggressiveness and malignant potential of prostate cancer cells...